+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen

POWERPIINC (PreOperative Window of Endocrine TheRapy Provides Information to Increase Compliance) trial: Changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen

Breast 31: 219-223

A decrease in Ki67 during neoadjuvant therapy predicts response to tamoxifen. Previous trials have shown a decreased Ki67 in breast tumors with as little as two or more weeks of preoperative tamoxifen. Shortening the preoperative treatment time in window of opportunity clinical trials makes these trials more attractive to women. POWERPIINC examined the effect of 7 days of preoperative tamoxifen on breast tumor proliferation and patient symptoms. Women with untreated stage I/II, ER-positive, invasive breast cancer with no contraindications to tamoxifen were enrolled. Women received 20 mg of tamoxifen for 7 days up to the day of surgery. Proliferation was assessed by Ki67 immunohistochemistry before and after 7 days of tamoxifen. Symptoms and QOL were assessed by the FACT-ES and MENQOL. Adherence was measured by pill counts. 52 women were enrolled, and 44 were evaluable for Ki67. The median age was 58.5 years, and the median tumor diameter was 1.2 cm. Most women (73%) were post-menopausal. Most tumors were PR positive (88%) and HER2-negative (92%). The Ki67 decreased by a geometric mean of 40% (95% CI 29%-63%), and 73% (95% CI 57%-85%) of women had tumors with decreased proliferation (p = 0.0001 by paired t-test). Adherence to taking tamoxifen during the preoperative period was 100%. Women reported minimal bother from psychosocial or physical symptoms at baseline or on the day of surgery. Seven days of tamoxifen showed a similar relative decrease in Ki67 as that reported for longer courses, was acceptable to women, and could be considered for window of opportunity studies.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 058494741

Download citation: RISBibTeXText

PMID: 27915204

DOI: 10.1016/j.breast.2016.11.016

Related references

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer 106(10): 2095-2103, 2006

Five-year quality of life (QOL) follow-up of adjuvant endocrine therapy for postmenopausal women in the Arimidex (A), Tamoxifen (T), Alone or in Combination (ATAC) Trial. Journal of Clinical Oncology 23(16_Suppl): 577-577, 2016

Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients. Breast Cancer 21(5): 557-562, 2014

Quality of Life Outcomes From a Phase 2 Trial of Short-Course Radiation Therapy Followed by FOLFOX Chemotherapy as Preoperative Treatment for Rectal Cancer. International Journal of Radiation Oncology Biology Physics 95(5): 1429-1438, 2016

Preoperative chemoradiotherapy versus preoperative radiotherapy in rectal cancer patients: assessment of acute toxicity and treatment compliance. Report of the 22921 randomised trial conducted by the EORTC Radiotherapy Group. European Journal of Cancer 40(2): 219-224, 2004

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. Journal of Clinical Oncology 23(22): 5108-5116, 2005

Decrease of serum hemoglobin during dose-intensified preoperative chemotherapy has no influence on tumor response Results from the German preoperative adriamycin/docetaxel trial. Breast Cancer Research & Treatment 69(3): 243, 2001

Preoperative adjuvant therapy for urinary bladder cancer--preoperative intra-arterial anticancer drugs infusion using artificial liver, and preoperative radiotherapy. Nihon Hinyokika Gakkai Zasshi. Japanese Journal of Urology 81(9): 1404-1411, 1990

Remission rate and toxicity of preoperative therapy with concurrent application of tamoxifen together with adriamycin and docetaxel in comparison to chemotherapy alone Results of the phase IIB - GEPARDO trial. Breast Cancer Research & Treatment 64(1): 67, 2000

Effect of preoperative pelvic floor muscle therapy with biofeedback versus standard care on stress urinary incontinence and quality of life in men undergoing laparoscopic radical prostatectomy: a randomised control trial. Neurourology and Urodynamics 34(2): 144-150, 2015

Outpatient preoperative examination by the anesthesiologist. I. Fewer procedures and preoperative hospital days. Nederlands Tijdschrift Voor Geneeskunde 139(20): 1028-1032, 1995

Evaluation of the effectiveness of preoperative radiation therapy of esophageal cancer according to the tumor lesion index. Meditsinskaia Radiologiia 23(11): 3-6, 1978

Does a Preoperative Educational Class Increase Patient Compliance. Geriatric Orthopaedic Surgery and Rehabilitation 6(3): 153-156, 2015

Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial. RadioTherapy and Oncology 84(3): 217-225, 2007